Therapeutic Advances in Psychopharmacology

作者须在投稿过程中列出每位作者的贡献，并在致谢部分之后加入“作者贡献”标题；投稿时填写的信息将在校对阶段显示于该标题下。 模型中文摘要

You will be asked to list the contribution of each author as part of the submission process. Please include the Author Contributions heading within your submission after the Acknowledgements section. The information you give on submission will then show under the Author Contributions heading later at the proofing stage.

在符合伦理和法律要求的前提下，期刊鼓励作者将研究数据存入相关公共数据仓库、提供链接数据的数据可用性声明（无法共享时须说明原因），并在论文中引用该数据。 模型中文摘要

The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…

作者须在指定标题下提供伦理批准声明，即使方法部分已包含相关信息；如无需伦理批准须明确说明。涉及人类参与者、人类数据或人体组织的研究须声明相关伦理委员会或机构审查委员会批准或豁免，并提供委员会全称、所属机构及批准号。 模型中文摘要

Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…

本网站上的稿件内容依据知识共享许可协议授权。 模型中文摘要

Manuscript content on this site is licensed under Creative Commons Licenses

Therapeutic Advances in Psychopharmacology 是开放获取、同行评审期刊，录用文章发表后立即免费在线提供，采用知识共享许可并永久在线保存；录用后须支付一次性文章处理费（APC），由资助方、机构或作者承担，投稿不收费，标准 APC 为 3,200 美元。 模型中文摘要

Therapeutic Advances in Psychopharmacology is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable to cover the cost of publis…

该期刊采用单盲同行评审：审稿人与编辑互动，不公布审稿信息；稿件先经初步评估，不符合指南要求的稿件将被退回修改，超出范围或不合适的稿件可能未经同行评审即被拒稿，通过初评后进入同行评审。 模型中文摘要

The following summary describes the peer review process for this journal: Identity transparency:Single-anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk reject…

期刊和 Sage 高度重视版权侵犯、抄袭及其他违反出版最佳实践的行为，作者应阅读 Sage 关于抄袭的完整政策及其可能采取的措施。 模型中文摘要

The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.

期刊接受已在预印本服务器发布的稿件；投稿时须在指定字段填写预印本 DOI，并建议在投稿时告知编辑部；同行评审期间不应在预印本服务器发布更新版本。 模型中文摘要

The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…

期刊遵循 ICMJE 要求：临床试验须在纳入首位受试者时或之前在 WHO 认可的公共试验注册机构注册，作为考虑发表的条件；试验注册机构名称、网址及注册号须列于摘要末尾。 模型中文摘要

The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.